JRSBRT HomeIssue Contents

Stereotactic body radiotherapy for stage I non-small cell lung cancer
Ben J. Slotman

In this manuscript, developments in the techniques, clinical outcome, toxicity, and future perspectives of SBRT for medically inoperable and operable early stage NCSLC are discussed. SBRT is well tolerated and has limited and acceptable side effects. It has evolved as a standard of care for medically inoperable patients. These excellent results taken together with the morbidity and mortality associated with surgery, might also lead to changes in the treatment for operable patients.

Keywords: Lung cancer, NSCLC, SBRT, review

Full Text (IP)
Purchase Article (PDF)